ABEO ABEONA THERAPEUTICS INC.

BEARISH Impact: 5/10 Insider Cluster (4 insiders)
Horizon weeks Filed Jun 10, 2026 Processed 5d 8h ago
Insider cluster: 2 insiders, $159K total

Price Chart

Loading chart...

Executive Summary

A cluster of insider sales at ABEO Therapeutics: CEO, CFO, Chief Commercial Officer, and Chief Legal Officer collectively sold ~$540K in open-market transactions over two days (June 8-9, 2026) at ~$5.30-$5.43/share. While the dollar amount is modest relative to the $307M market cap (~0.18%), the participation of the entire C-suite in a coordinated sell-off is notable. The cluster is amplified by cross-filing context (cluster-insider-trades + cluster-offering-context), suggesting potential upcoming dilutive activity or other material developments.

Key Financial Metrics

Direction
selling
Total Value
$540.0K
Insiders
4

Actionable Insight

The simultaneous C-suite sell-off at a biotech with 92% analyst bullishness is a red flag. Monitor for an S-3 shelf filing or other dilutive offering in the next 30 days — the cross-filing actuarial verdicts strongly amplify this cluster's signal. If no offering materializes within 2 weeks, the sales may be tax/planning related, but the coordination warrants caution.

Key Facts

  • CEO Vishwas Seshadri sold 56,344 shares for ~$302K on June 8-9.
  • CFO Joseph Vazzano sold 23,692 shares for ~$127K on June 8-9.
  • Chief Commercial Officer Madhav Vasanthavada sold 9,620 shares for ~$52K on June 8-9.
  • SVP/Chief Legal Officer Brendan O'Malley sold 11,131 shares for ~$60K on June 8-9.
  • Total insider sales of ~$540K represent ~0.18% of ABEO's $307M market cap.
  • All four C-suite officers sold on both June 8 and June 9 at similar prices, suggesting coordinated timing.
  • Cross-filing context shows cluster-insider-trades + cluster-offering-context as an amplifier, raising the probability of a near-term dilutive offering.

Financial Impact

~$540K in insider sales, ~0.18% of market cap

dilution riskinsider sentiment

Risk Factors

  • Potential near-term dilutive equity offering signaled by cross-filing amplifier
  • C-suite selling at a price near recent highs (~$5.43) may indicate insider view that stock is fairly valued or overvalued
  • Historical calibration shows score-6 filings in this segment have only 34% observed up-move probability at T+20, with negative net alpha

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ABEO-1781051614054
12 reports for ABEO
Performance horizon
Filters
Rows
Reports for ABEO — sortable, filterable
Type Now
Jun 12, 2026
2d ago
8-K
NEUTRAL ★ 2/10
$5.54 awaiting T+1awaiting T+1$5.53 (−0.18%)
Jun 10, 2026
4d ago
8-K
NEUTRAL ★ 2/10
$5.35 awaiting T+1awaiting T+1$5.53 (+3.36%)
Jun 10, 2026
5d ago
Insider Cluster
BEARISH ★ 5/10
$5.45 awaiting T+1awaiting T+1$5.53 (−1.56%)
Jun 4, 2026
10d ago
8-K
NEUTRAL ★ 4/10
$5.82 $5.46▼ −6.19%▼ −3.59%$5.53 (−4.98%)
May 22, 2026
23d ago
Insider Cluster
NEUTRAL ★ 2/10
$5.49 $5.69▲ +3.64%▲ +3.63%$5.53 (+0.73%)
May 13, 2026
4w ago
8-K
NEUTRAL ★ 5/10
$5.71 $5.60▼ −1.93%▼ −2.70%$5.53 (−3.15%)
May 13, 2026
4w ago
Press Release
NEUTRAL ★ 5/10
$5.71 $5.60▼ −1.93%▼ −2.70%$5.53 (−3.15%)
May 4, 2026
5w ago
DEFA14A
NEUTRAL ★ 2/10
$5.83 $6.01▲ +3.09%▲ +1.70%$5.53 (−5.15%)
Apr 7, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$4.81 $4.87▲ +1.25%▼ −1.29%$5.53 (+14.97%)
Apr 2, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$4.82 $4.76▼ −1.24%▼ −1.72%$5.53 (+14.73%)
Showing 10 of 12

US Market Status

Market Closed — Opens in 4h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access